Trial Profile

Phase II/III study of Rimeporide

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 03 May 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rimeporide (Primary)
Indications Duchenne muscular dystrophy
Focus Therapeutic Use

Most Recent Events

03 May 2018 New trial record
16 Mar 2018 According to an EspeRare Foundation media release, this trial is expected to at the end of 2018/early 2019, depending on funding.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com